- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
BIND Biosciences announced today the presentation of its Medicinal Nanoengineering™ platform at the ACS National Meeting, including results from preclinical studies on its lead nanomedicine drug, BIND-014, scheduled to enter clinical trials later this year.
BIND-014 is a targeted, polymeric nanoparticle containing the cytotoxic agent, docetaxel, which is approved in major cancer indications, including breast, prostate and lung. In animal models of human cancers, BIND-014 was shown to deliver up to 20 times more docetaxel to the tumor site than an equivalent dose of Taxotere®. The increased accumulation of docetaxel at the site of disease was shown in preclinical models to lead to marked improvements in antitumor activity and tolerability.
At the ACS National Meeting, Dr. Jeff Hrkach, Senior Vice President of Pharmaceutical Sciences at BIND, will present the latest preclinical data showing the efficacy of BIND-014, as well as presenting results of preclinical studies using the company's Medicinal Nanoengineering proprietary technology for BIND's drug candidates in oncology, inflammatory diseases and cardiovascular disorders. The presentation will be part of a three-day symposium on the advancement of nanomedicine at the ACS National Meeting, taking place in Boston from August 22 through August 26. Dr. Hrkach's presentation, "High-precision therapeutics through Medicinal Nanoengineering," will be Tuesday, August 24 at 3:55 PM in The Westin Boston Waterfront, Grand Ballroom C.
In addition, both of BIND's scientific co-founders, Dr. Robert Langer, MIT David H. Koch Institute Professor, and Dr. Omid Farokhzad, Harvard Medical School Associate Professor, have been invited to present at the nanomedicine symposium at the ACS.
* Dr. Langer delivered the opening keynote address for the nanomedicine symposium, "Nanotechnology and its potential in medicine," on Sunday, August 22.
* Dr. Farokhzad will make a presentation, "Medical nanoengineering: Multifunctional polymeric nanoparticles for medical applications," on Monday, August 23, with the results and drug discovery translation of his pioneering academic research in nanomedicine technology.
"As our recent data show, BIND's Medicinal Nanoengineering approach has the potential to significantly improve upon the traditional drug development process and produce best-in-class new drugs," said Jeff Hrkach, Senior VP at BIND. "We have shown in preclinical studies with BIND-014 and other drug candidates that our platform can produce more effective, less toxic drugs by targeting our drug compounds precisely to the site of disease."
About BIND Biosciences
BIND Biosciences, Inc., is a biopharmaceutical company leveraging its proprietary Medicinal Nanoengineering platform to produce best-in-class drugs to provide significant improvement in the treatment of patients with serious diseases. BIND’s platform enables the design, engineering and manufacturing of therapeutic targeted nanoparticles with unprecedented control over drug pharmacokinetics, biodistribution and cell- or tissue-specific targeting. Medicinal Nanoengineering complements medicinal chemistry to enable predictable, cost effective and rapid development of breakthrough products with superior efficacy and safety profiles. Product opportunities include enabling or expediting the development of pipeline molecules as well as improving performance, expanding indications or life cycle extension for mid- and late-stage products. BIND’s initial product development efforts are in the areas of oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics. BIND is working both on nanoengineered forms of approved drugs and with pharmaceutical partners on drugs in development. BIND’s lead program, BIND-014, targets a surface protein upregulated in solid tumors and is planned to enter clinical development in 2H 2010.
BIND was founded in 2006 by two pioneers in the field of therapeutic targeted nanoparticles, Dr. Robert Langer and Dr. Omid Farokhzad. BIND is backed by leading venture capital firms, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments and Endeavour Vision.
For more information, please click here
BIND Biosciences, Inc.
Andrea Franz, 617-491-3400
The Yates Network
Kathryn Morris, 845-635-9828
Copyright © Business WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Nanoparticles simplify DNA identification and quantification November 27th, 2015
Scientists 'see' detailed make-up of deadly toxin for the first time: Exciting advance provides hope for developing novel potential method of treating pneumococcal diseases such as bacterial pneumonia, meningitis and septicaemia November 25th, 2015
Stanford technology makes metal wires on solar cells nearly invisible to light November 27th, 2015
Nanometrics Announces Upcoming Investor Events November 18th, 2015
FEI and ICON Analytical Demonstrate the Power of TEM for Materials and Life Sciences Research: FEI’s Talos scanning transmission electron microscope will be available for demos and workshops at the Indian Institute of Science from 23 November to 15 December 2015 November 17th, 2015
Electric fields remove nanoparticles from blood with ease November 24th, 2015
Breakthrough allows tracking of single molecules in 3-D with nanoscale accuracy:New method builds on Nobel Prize-winning technique, with exciting implications for understanding the inner workings of cells and neurons November 23rd, 2015